Immunogenicity of the Recombinant Zoster Vaccine (Shingrix ®) in Multiple Sclerosis Patients Treated With Anti-CD20 Antibodies Compared to Controls- a Phase IV Monocentric Study
Latest Information Update: 16 Apr 2024
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
- Acronyms MSHINGVAX
Most Recent Events
- 08 Apr 2024 Planned End Date changed from 1 Nov 2024 to 31 Dec 2025.
- 08 Apr 2024 Planned primary completion date changed from 1 Nov 2024 to 31 Dec 2024.
- 08 Apr 2024 Status changed from not yet recruiting to recruiting.